2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
May 15, 2024
Video
Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.
May 15, 2024
Video
The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.
May 13, 2024
Article
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
May 10, 2024
Video
Bradley R. Corr, MD, discusses a phase 2 study evaluating rucaparib maintenance therapy in patients with metastatic and recurrent endometrial cancer.
May 08, 2024
Video
Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.
May 08, 2024
Video
Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.
May 01, 2024
Video
Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.
May 01, 2024
Video
Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.
April 26, 2024
Video
Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.
April 26, 2024
Video
Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.
April 24, 2024
Video
Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
April 24, 2024
Video
The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.
April 19, 2024
Article
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
September 27, 2023
Video
S. Alex Mastroyannis, MD, MSCE, discusses the administration and role of hyperthermic intraperitoneal chemotherapy in ovarian cancer, as well as its benefit for patients in the phase 3 OVHIPEC-1 trial.
September 25, 2023
Video
Institutional Perspectives in Cancer: Gyn/Onc - Chaired by Saketh Guntupalli, MD
September 20, 2023
Video
D. Ross Camidge, MD, PhD, discusses the rationale for the ongoing phase 2 TRUST-II trial of taletrectinib in patients with non–small cell lung cancer harboring ROS1 mutations.
August 24, 2023
Podcast
In this episode of "How This Is Building Me," Drs Camidge and Vokes discuss the span of countries and institutions along Dr Vokes’ journey to MD Anderson Cancer Center, how Dr Vokes balances research and work in the clinic, and how the correct mentors can help shape career paths in oncology.
August 24, 2023
Article
Breelyn Wilky, MD, discusses the rationale for investigating the addition of doxorubicin to zalifrelimab and balstilimab in patients with advanced/metastatic soft tissue sarcoma, expands on results from the phase 2 trial, and emphasizes the need for continued research for the potential role of immunotherapy in this patient population.
August 11, 2023
Article
The combination of teclistamab and nirogacestat produced high and deep responses in patients with relapsed/refractory multiple myeloma.
July 24, 2023
Podcast
Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.